GlassScriptPhysician profile
Sukanya Somasundar
NPI 1437173572
$12,418.58
in general payments reported to CMS, 2019-2025
72 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $882 · 2021: $2,563 · 2022: $2,836 · 2023: $2,388 · 2024: $1,256 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,542.32 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,489.89 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Pfizer INC. | $1,064.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $807.45 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Novo Nordisk INC | $718.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $665.78 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $646.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $470.92 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $433.64 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $348.21 | 2019-2024 | Veozah, Xtandi, Padcev |
| Janssen Biotech, INC. | $225.57 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Nestle Healthcare Nutrition INC. | $213.78 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $190.81 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $178.29 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $159.75 | 2022-2024 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukanya Somasundar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.